Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3499 publications

Human papillomavirus-related conditions in women with multiple sclerosis receiving disease-modifying therapies: A Pharmacovigilance disproportionality analysis from the WHO vigibase®.

Human papillomavirus-related conditions in women with multiple sclerosis receiving disease-modifying therapies: A Pharmacovigilance disproportionality analysis from the WHO vigibase®.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: October 08, 2025

IRIS without PML in MS patients - a case report of IRIS after past alemtuzumab therapy with subsequent oral cladribine treatment and review of the literature.

IRIS without PML in MS patients - a case report of IRIS after past alemtuzumab therapy with subsequent oral cladribine treatment and review of the literature.

Journal: Annals of agricultural and environmental medicine : AAEM
Published: September 30, 2025

JC virus PCR assay reporting for PML: promises, perils, and pitfalls.

JC virus PCR assay reporting for PML: promises, perils, and pitfalls.

Journal: Journal of neurology
Published: September 16, 2025

Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability.

Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability.

Journal: JAMA network open
Published: September 15, 2025

Modulation of Paraoxonase 1 Activity and Asymmetric Dimethylarginine by Immunomodulatory Therapies in Multiple Sclerosis.

Modulation of Paraoxonase 1 Activity and Asymmetric Dimethylarginine by Immunomodulatory Therapies in Multiple Sclerosis.

Journal: International journal of molecular sciences
Published: September 03, 2025

Natalizumab-Associated Progressive Multifocal Leukoencephalopathy After Natalizumab Extended Interval Dosing Therapy in Japan.

Natalizumab-Associated Progressive Multifocal Leukoencephalopathy After Natalizumab Extended Interval Dosing Therapy in Japan.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: August 28, 2025

Proinflammatory Effect of Mesenchymal Stem Cells From Patients With Multiple Sclerosis: Potential Modulation Targets.

Proinflammatory Effect of Mesenchymal Stem Cells From Patients With Multiple Sclerosis: Potential Modulation Targets.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: August 28, 2025

Effect of Early Treatment Intensity on Progression Independent of Relapse Activity and Disability Accumulation in Multiple Sclerosis.

Effect of Early Treatment Intensity on Progression Independent of Relapse Activity and Disability Accumulation in Multiple Sclerosis.

Journal: medRxiv : the preprint server for health sciences
Published: August 12, 2025

Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis.

Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis.

Journal: Neurology
Published: August 07, 2025

Natalizumab for multiple sclerosis.

Natalizumab for multiple sclerosis.

Journal: The Cochrane database of systematic reviews
Published: August 06, 2025

Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.

Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.

Journal: JAMA neurology
Published: August 04, 2025

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.

Journal: Neurology
Published: July 30, 2025
Showing 1-12 of 3,499

Last Updated: 10/31/2025